Watch Dr Martin Maron and Dr Iacopo Olivotto as they discuss key findings from the phase 3 EXPLORER-HCM trial which looks at the treatment effect of first-in-class cardiac myosin inhibitor, mavacamten, in patients with symptomatic obstructive HCM.
Topic
EXPLORER-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of the first targeted pharmacological therapy designed specifically to address the primary underlying pathophysiological basis of obstructive hypertrophic cardiomyopathy.
This 30-minute journal club explored the insights and impact of how the results of this pivotal trial supports a role for disease-specific therapy for obstructive HCM which treats the cause instead of just managing symptoms. The results of the global, phase 3 EXPLORER-HCM trial were presented at the European Society of Cardiology (ESC) Congress 2020 and simultaneously published in The Lancet.
Target audience
This educational activity is designed for cardiologists, cardiac surgeons, general physicians, cardiac nurses, and any other healthcare professional with an interest in HCM patients or cardiology.
Learning objectives
Listen to Dr Martin Maron open up Heart Education USA’s first journal club and the key objectives of the webinar.
Watch Dr Iacopo Olivotto discuss the treatment of obstructive HCM in the EXPLORER-HCM trial.
In this video, Dr Olivotto talks about the mode of action of mavacamten in patients with symptomatic obstructive HCM and the key findings from the EXPLORER-HCM trial.
Listen to Dr Maron and Dr Olivotto discuss questions submitted directly live from the audience. Featured questions include:
